Bayer Healthcare LLC

Bayer Pharmaceuticals Corporation

Bayer Corporation

Harold C E Kluender

Julie A Dixon

Barton W Phillips

Steven R Magnuson

Brent Chandler

Ning Miao Su

Dhanapalan Nagarathnam

Jacques P Dumas

Wendy Lee

Stephen J O'Connor

Kyle E Parcella

Robert Sibley

Zhonghua Zhang

Stephen Boyer

Jason S Newcom

Teddy Kite Joe

Zhenqiu Hong

Catherine R Brennan

Furahi Achebe

Benjamin Jones

Uday R Khire

Zheng Liu

Jianmei Fan

Martin Michels

Michael Brands

Donald Bierer

Karl Miranda

Wenlang Fu

Lei Wang

Andrea McClure

Roger Astbury Smith

William Johnston Scott

Gan Wang

Wai C Wong

Donald J Wolanin

Soongyu Choi

Klaus Urbahns

David R Brittelli

Brian R Dixon

Peiying Liu

William H Bullock

Robert B Dally

Yamin Wang

Holia Hatoum-Mokdad

Cedo Martin Bagi

Jeffrey Johnson

Stephan-Nicholas Wirtz

Shihong Ying

Jinshan Chen

Kristen M Allegue

Tindy Li

Anik&oacute; M Redman

William F Lathrop

William L Collibee

Carol Ann Mase

Zhen Liu

This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

This invention relates to pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.

Substituted and pyridines and pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; Rand Rmay be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.

Substituted pyridines and pyridazines with angiogenesis inhibiting activity

This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

Preparation and use of imidazole derivatives for treatment of obesity

Substituted and Fused pyridazines having angiogenesis inhibiting activity and the generalized structural formulawherein the ring containing A, B, D, E, and L is a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; Rand Rmay be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.

Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

Growing community of inventors

Trumbull, CT, United States of America

Harold C E Kluender